drugset
drugset / Trial / NCT06265025

GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors

NCT06265025 ↗

Phase 1/2 Recruiting 125 enrolled GeneMedicine Co., Ltd.
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to measure safety, tolerability, and preliminary antitumor efficacy of GM103 administered alone and in combination with pembrolizumab in patients with locally advanced, unresectable, refractory and/or metastatic solid tumors (including but not limited to head and neck cancer, malignant melanoma, CRC, renal cell carcinoma, cervical cancer, and breast cancer). Study details include:

Timeline

Start
2024-02-20
Primary completion
2025-05-30
Completion
2028-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject GM103 Unknown 1e+11 unknown Other
Subject GM103 Unknown 3e+11 unknown Other
Subject GM103 Unknown 1e+12 unknown Other
Subject GM103 Unknown 3e+12 unknown Other
Subject Pembrolizumab Monoclonal antibody 200 mg —

Indications

breast cancer cervical cancer colorectal cancer head and neck cancer melanoma renal cell carcinoma